- Conditions
- Brain Tumor
- Interventions
- Letrozole Oral Tablet, Temozolomide
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 179
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Keratitis, Corneal Ulcer
- Interventions
- Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
- Combination Product · Other
- Lead sponsor
- Peschke GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
- Conditions
- Metastatic Melanoma
- Interventions
- Pembrolizumab, Infliximab, Placebo, Relatlimab, Nivolumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer
- Interventions
- MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 70
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Atezolizumab, Biospecimen Collection, Capecitabine, Computed Tomography, Docetaxel, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Lymphadenectomy, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Surgical Procedure
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 133
- States / cities
- Dublin, California • Fremont, California • Fresno, California + 99 more
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pacritinib, Physician's Choice medications
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
- Conditions
- Locally Advanced or Metastatic Unresectable Urothelial Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 17 more
- Conditions
- Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)
- Interventions
- Sofia 2 Lyme FIA testing
- Device
- Lead sponsor
- Quidel Corporation
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 11
- States / cities
- Fall River, Massachusetts • South Westport, Massachusetts • Duluth, Minnesota + 7 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more
- Conditions
- Breast Neoplasms, Malignant Tumor of the Breast
- Interventions
- Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Texas
- Conditions
- Myelodysplastic Syndromes
- Interventions
- FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
- Drug · Other · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Sarcoma
- Interventions
- Preoperative RT, Postoperative RT, Chemotherapy, Surgery
- Device · Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pancreatic Cancer
- Interventions
- SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
- Drug
- Lead sponsor
- Tyme, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
- Combination Product · Biological · Drug
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- (vic-)trastuzumab duocarmazine, Physician's choice
- Drug
- Lead sponsor
- Byondis B.V.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Tucson, Arizona • San Diego, California + 17 more
- Conditions
- Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 365
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more
- Conditions
- Gastroesophageal Cancer
- Interventions
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
- Conditions
- Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more
- Conditions
- Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
- Interventions
- Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
- Radiation · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
- Conditions
- Endometrioid Endometrial Adenocarcinoma
- Interventions
- Glucagon-like peptide 1 receptor agonist
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Adverse Drug Events
- Interventions
- Basic Clinical Decision Support, Routine Care
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 228 participants
- Timeline
- 2001 – 2007
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Triple-Negative Breast Cancer (TNBC)
- Interventions
- BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
- Drug
- Lead sponsor
- BreakBio Corp
- Industry
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Stage IV Non-Small Cell Lung Cancer
- Interventions
- Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
- Radiation · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California